This proposal is a request for continued partial funding of the Flow Cytometry Core Facility (FCCF) within the Multipurpose Arthritis & Musculoskeletal Disease Center (MAMDC). The primary purpose of the FCCF is to make available to MAMDC investigators access to the equiment, trained personnel and expertise to perform cell analysis and purification with state-of-the-art equipment and techniques on a reasonable cost for services basis. The FCCF serves over 120 individuals per year. Although the FCCF is open to all UAB researchers, service to MAMDC investigators accounts for approximately 80% of center operations. At the present time the FCCF contains a FACScan five parameter single laser analytical cytometer and a FACStar(plus) six parameter, dual laser cytometer/sorter. The computers which control these instruments have been networked for efficiency, and a variety of programs for univariate through tetravariate fluorescence analysis, DNA curve fitting, immune monitoring and numerous other applications are available. The MAMDC FCCF and the University of Alabama AIDS Center Flow Cytometry Facility are operated jointly. This results in improved service to investigators through increased flexibility in equiment and personnel. Disruption due to equipment maintenance or leave of absence of personnel are minimized. The facilities jointly employ an Associate Core Director (MLS) and a lab manager (GQH) who are both experienced cytometer operators. Funds are requested to ensure stable support for 50% of the operators' salaries for the operators, and to cover a portion of the field service contracts for the cytometers. The requested level of support will be sufficient to cover approximately 50% of the actual cost of operating the FCCF. This will allow the present rate of $50/hour for MAMDC investigators to be sustained into the foreseeable future.

Project Start
1999-01-01
Project End
1999-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68
Rayburn, Elizabeth R; Wang, Wei; Zhang, Zhuo et al. (2006) Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 66:1653-63

Showing the most recent 10 out of 145 publications